CVSNYSERetail-Drug Stores and Proprietary StoresFiscal year ends December 31
CVS HEALTH Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$92.68+0.32 (+0.35%)
Close on Oct 19, 2026
- Market cap
- $119.28B
- P/E (TTM)
- 24.6
- Dividend yield
- 2.87%
CVS HEALTH Corp revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Health Services | $190.43B | $173.61B | $186.84B | $169.58B | $153.89B | – | – | – | – | – | 47.4% | +9.7% |
| Health Care Benefits | $143.35B | $130.67B | $105.65B | $91.35B | $82.12B | $75.47B | $69.60B | $8.96B | $3.59B | $0 | 35.7% | +9.7% |
| Pharmacy & Consumer Wellness | $139.37B | $124.50B | $116.76B | $108.60B | $101.62B | – | – | – | – | – | 34.7% | +11.9% |
| Corporate Segment | – | – | – | – | – | – | – | – | – | $0 | – | – |
| Retail/LTC Segment | – | – | – | – | – | – | – | – | $79.40B | $81.10B | – | – |
| Pharmacy Services | – | – | – | $169.24B | $153.02B | $141.94B | $141.49B | $134.74B | $130.82B | $119.97B | – | – |
| Retail LTC | – | – | – | $106.59B | $100.11B | $91.20B | $86.61B | $83.99B | $79.40B | $81.10B | – | – |
| Corporate/ Other | – | – | – | – | – | – | $512.00M | $606.00M | $16.00M | $18.00M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Health Care Benefits | – | – | – | – | – | – | – | $276.00M | $0 | $0 | – |
| Corporate Segment | – | – | – | – | – | – | – | – | -$966.00M | -$891.00M | – |
| Retail/LTC Segment | – | – | – | – | – | – | – | – | $6.47B | $7.30B | – |
| Pharmacy Services | – | – | – | – | – | – | – | $4.70B | $4.66B | $4.57B | – |
| Retail LTC | – | – | – | – | – | – | – | $620.00M | $6.56B | $7.44B | – |
| Corporate/ Other | – | – | – | – | – | – | – | -$805.00M | -$936.00M | -$900.00M | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Products | $249.91B | $231.52B | $245.14B | $226.62B | $203.74B | $190.69B | $185.24B | $183.91B | $180.06B | $173.38B | 62.2% | +7.9% |
| Services | $15.18B | $16.24B | $12.29B | $9.68B | $11.04B | $7.86B | $7.41B | $1.83B | $1.14B | $1.08B | 3.8% | -6.6% |
| Premiums | – | – | – | – | – | – | $63.12B | $8.18B | $3.56B | $3.07B | – | – |
| Front Store | – | – | – | – | – | – | $19.42B | $19.06B | – | – | – | – |
| Pharmacy | – | – | – | – | – | – | $165.90B | $164.85B | – | – | – | – |
| Other | – | – | – | – | – | – | $7.32B | $1.84B | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Cvs Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.